Fate Therapeutics Receives Analyst Hold Rating

Summary

Fate Therapeutics, Inc. (NASDAQ: FATE) has received an average ‘hold’ rating from eight analysts, with seven holding the stock and one buying it. The 12-month average target price is $3.83. Recent reports include a target of $5.00 from Wedbush and a reduced target of $2.00 from Barclays. The stock opened at $1.19 with a market cap of $136.37 million. Institutional investors hold 97.54% of the stock. Fate Therapeutics develops cell therapies for cancer and immune diseases.Market Beat

Impact Analysis

This event is classified at the company level, as it relates to analyst ratings and stock price targets specific to Fate Therapeutics. The ‘hold’ rating suggests that analysts do not foresee significant upward or downward movement in the stock in the near term. The variability in target prices from Wedbush ($5.00) and Barclays ($2.00) indicates differing views on the company’s prospects, reflecting uncertainty. With a small market cap and high institutional ownership, any significant changes in institutional sentiment could lead to stock volatility. The fact that Fate Therapeutics is not among the top picks for analysts (as reported by Marketbeat) might suggest limited immediate investment enthusiasm. Investors should monitor institutional actions and any new developments in the company’s therapeutic pipeline for potential indicators of stock movement.Market Beat+ 3